X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1347) 1347
Publication (132) 132
Book Review (23) 23
Book Chapter (5) 5
Magazine Article (5) 5
Conference Proceeding (4) 4
Reference (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1107) 1107
nootropic agents - therapeutic use (866) 866
male (696) 696
index medicus (667) 667
female (573) 573
nootropic agents - adverse effects (553) 553
aged (479) 479
alzheimer disease - drug therapy (474) 474
animals (356) 356
pharmacology & pharmacy (324) 324
neurosciences (316) 316
alzheimer's disease (309) 309
treatment outcome (308) 308
middle aged (298) 298
nootropic agents - pharmacology (298) 298
nootropic agents - administration & dosage (272) 272
psychiatry (272) 272
dementia (270) 270
clinical neurology (256) 256
donepezil (247) 247
alzheimers-disease (243) 243
cognition - drug effects (237) 237
piperidines - therapeutic use (229) 229
double-blind (226) 226
indans - therapeutic use (226) 226
cholinesterase inhibitors - therapeutic use (214) 214
double-blind method (213) 213
aged, 80 and over (211) 211
adult (207) 207
neuropsychological tests (193) 193
memory (167) 167
cognition (165) 165
rats (163) 163
piperidines - adverse effects (160) 160
indans - adverse effects (156) 156
cognition disorders - drug therapy (145) 145
geriatrics & gerontology (145) 145
cholinesterase inhibitors - adverse effects (144) 144
alzheimer disease - psychology (139) 139
dose-response relationship, drug (132) 132
efficacy (123) 123
mice (119) 119
placebo-controlled trial (118) 118
drug therapy (115) 115
analysis (113) 113
galantamine - therapeutic use (104) 104
rivastigmine (104) 104
brain (100) 100
randomized controlled trials as topic (100) 100
memory - drug effects (99) 99
brain - drug effects (96) 96
dementia - drug therapy (92) 92
disease models, animal (88) 88
galantamine (88) 88
neurology (88) 88
alzheimer disease - diagnosis (86) 86
clinical trials as topic (86) 86
medicine, general & internal (85) 85
alzheimers disease (82) 82
article (82) 82
drug therapy, combination (82) 82
clinical trials (81) 81
memantine - therapeutic use (79) 79
time factors (77) 77
memantine (76) 76
severity of illness index (74) 74
research (73) 73
gerontology (72) 72
cholinesterase inhibitors (71) 71
cognitive ability (71) 71
drugs (70) 70
maze learning - drug effects (69) 69
safety (68) 68
adolescent (67) 67
galantamine - adverse effects (67) 67
young adult (65) 65
care and treatment (64) 64
follow-up studies (63) 63
neuroprotective agents - therapeutic use (63) 63
health aspects (62) 62
rats, wistar (62) 62
cognition disorders - etiology (61) 61
schizophrenia (61) 61
memory disorders - drug therapy (60) 60
nootropic agents - pharmacokinetics (60) 60
piperidines - administration & dosage (60) 60
impairment (57) 57
indans - administration & dosage (57) 57
activities of daily living (56) 56
cholinesterase-inhibitors (56) 56
behavior, animal - drug effects (53) 53
performance (51) 51
pharmacology (51) 51
psychiatric status rating scales (50) 50
smart drugs and nutrients (50) 50
antipsychotic agents - therapeutic use (49) 49
disease progression (49) 49
moderate (48) 48
neurons - drug effects (48) 48
oxidative stress (48) 48
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1240) 1240
German (50) 50
Russian (35) 35
Japanese (10) 10
French (6) 6
Spanish (6) 6
Hungarian (5) 5
Danish (3) 3
Dutch (3) 3
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Clinical Nutrition, ISSN 0002-9165, 03/2015, Volume 101, Issue 3, pp. 538 - 548
Background: Recent evidence has indicated that flavanol consumption may have many health benefits in humans, including improved cognitive activities.... 
Lipid peroxidation | Insulin resistance | Cocoa flavanols | Blood pressure | Cognitive function | cognitive function | blood pressure | PROANTHOCYANIDINS | cocoa flavanols | PERFORMANCE | CHOCOLATE | FLAVAN-3-OLS | RICH COCOA | lipid peroxidation | IMPAIRMENT | CARDIOVASCULAR HEALTH | NUTRITION & DIETETICS | MOOD | INSULIN-RESISTANCE | insulin resistance | BRAIN | Beverages - adverse effects | Flavonols - adverse effects | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Flavonols - therapeutic use | Hypertension - drug therapy | Male | Cognition | Cognitive Dysfunction - prevention & control | Cacao - adverse effects | Aged, 80 and over | Aging | Female | Flavonols - administration & dosage | Hypertension - diet therapy | Double-Blind Method | Dairy Products - adverse effects | Cognitive Dysfunction - metabolism | Insulin Resistance | Nootropic Agents - therapeutic use | Combined Modality Therapy | Antihypertensive Agents - therapeutic use | Cacao - chemistry | Nootropic Agents - adverse effects | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Nootropic Agents - administration & dosage | Antioxidants - administration & dosage | Antioxidants - adverse effects | Aged | Lipid Peroxidation | Cohort Studies | Medical research | Flavonoids | Flavones | Bioflavonoids | Nutritional aspects | Medicine, Experimental | Research | Cocoa | Health aspects
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 433 - 444
The liver X receptors (LXRs) are pivotal regulators of lipid homeostasis in mammals. These transcription factors control the expression of a battery of genes... 
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Intestines - metabolism | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
Journal Article
The Journal of Nutritional Biochemistry, ISSN 0955-2863, 09/2017, Volume 47, pp. 1 - 20
Self-assembly of amyloid beta peptide (Aβ) into the neurotoxic oligomers followed by fibrillar aggregates is a defining characteristic of Alzheimer's disease... 
Amyloid beta | Phytochemicals | Biophenols | Alzheimer's disease | Neurodegenerative disorders | ANTIOXIDANT DEFENSE SYSTEM | BIOCHEMISTRY & MOLECULAR BIOLOGY | GINKGO-BILOBA EXTRACT | MILD COGNITIVE IMPAIRMENT | ROSMARINUS-OFFICINALIS L | NUTRITION & DIETETICS | AMYLOID-BETA-PEPTIDE | ACETYLCHOLINESTERASE-INHIBITORY-ACTIVITY | PLACEBO-CONTROLLED TRIAL | IONIZATION MASS-SPECTROMETRY | TRANSGENIC ANIMAL-MODELS | GREEN TEA POLYPHENOL | Neuroprotective Agents - therapeutic use | Stilbenes - adverse effects | Phytochemicals - therapeutic use | Oxidative Stress | Stilbenes - therapeutic use | Nootropic Agents - metabolism | Humans | Stilbenes - metabolism | Flavonoids - adverse effects | Flavonoids - therapeutic use | Neuroprotective Agents - metabolism | Phytochemicals - adverse effects | Plant Extracts - metabolism | Alzheimer Disease - prevention & control | Biomedical Research - methods | Neurons - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Phytochemicals - metabolism | Nootropic Agents - therapeutic use | Phenols - metabolism | Nootropic Agents - adverse effects | Antioxidants - therapeutic use | Animals | Phenols - adverse effects | Flavonoids - metabolism | Phenols - therapeutic use | Alzheimer Disease - metabolism | Models, Neurological | Plant Extracts - therapeutic use | Research Design | Plant Extracts - adverse effects | Oligomers | Peptides
Journal Article
Journal Article
Annual Review of Nutrition, ISSN 0199-9885, 7/2016, Volume 36, Issue 1, pp. 211 - 239
Moderately elevated plasma total homocysteine (tHcy) is a strong modifiable risk factor for vascular dementia and Alzheimer's disease. Prospectively, elevated... 
clinical trial | dementia | folate | cobalamin (vitamin B12) | cognition | Alzheimer's disease | PLASMA TOTAL HOMOCYSTEINE | BRAIN ATROPHY | ALZHEIMERS-DISEASE | FATTY-ACID-METABOLISM | RANDOMIZED CONTROLLED-TRIAL | NUTRITION & DIETETICS | SMALL-VESSEL DISEASE | MEDIAL TEMPORAL-LOBE | WHITE-MATTER HYPERINTENSITIES | PLACEBO-CONTROLLED TRIAL | TRANSIENT CEREBRAL-ISCHEMIA | Hyperhomocysteinemia - epidemiology | Folic Acid - therapeutic use | Folic Acid - adverse effects | Neurodegenerative Diseases - etiology | Nootropic Agents - metabolism | Humans | Neurodegenerative Diseases - prevention & control | Hyperhomocysteinemia - metabolism | Vitamin B 12 - adverse effects | Homocysteine - metabolism | Vitamin B 12 - therapeutic use | Cognitive Dysfunction - prevention & control | Hyperhomocysteinemia - physiopathology | Cognition Disorders - prevention & control | Cognition Disorders - etiology | Cognitive Dysfunction - epidemiology | Aging | Nutritional Status | Dietary Supplements - adverse effects | Vitamin B 6 - metabolism | Risk Factors | Homocysteine - blood | Nootropic Agents - therapeutic use | Cerebrovascular Circulation | Cognitive Dysfunction - etiology | Evidence-Based Medicine | Nootropic Agents - adverse effects | Animals | Neurodegenerative Diseases - physiopathology | Vitamin B 6 - adverse effects | Vitamin B 6 - therapeutic use | Biomarkers | Folic Acid - metabolism | Hyperhomocysteinemia - diet therapy | Cognition Disorders - epidemiology | Neurodegenerative Diseases - epidemiology | Vitamin B 12 - metabolism | Practice Guidelines as Topic | Physiological aspects | Homocysteine | Health aspects | Dementia
Journal Article